<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="COVID-19 adverse outcome pathway" Version="20200407" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Experimental pathway to investigate overlap of Covid-19 downstream effects and adverse outcome pathways related to lung injury.</Comment>
  <Comment Source="WikiPathways-description">Experimenting with links in line with bioinformatics analysis of COVID-19 genes and AOP knowledge. Work in progress!</Comment>
  <Graphics BoardWidth="1302.0" BoardHeight="892.0"/>
  <DataNode TextLabel="CCL3" GraphId="eb71b" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="Positive regulation of&#10;leukocyte activation" GraphId="c6c98" Type="Pathway" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="Toll-like&#10;receptor signaling" GraphId="cd4a3" Type="Pathway" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="TNF" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="Cytokines and&#10;inflammatory&#10;response" GraphId="f9a57" Type="Pathway" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="IL2" GraphId="d380c" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="CSF3" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL8" GraphId="cf7c5" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="CXCL10" GraphId="feac7" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL6" GraphId="f425c" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL7" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL1B" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="CCL2" GraphId="ee6e7" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL10" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="IL2RA" GraphId="f59b7" Type="GeneProduct" GroupRef="c757c">
        </DataNode>
  <DataNode TextLabel="LTF danger signal&#10;response pathway" GraphId="ace80" Type="Pathway" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="Lung fibrosis" GraphId="d20e7" Type="Pathway" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="SARS-CoV-2 and ACE2 receptor:&#10;molecular mechanisms and&#10;potential therapeutic target" GraphId="ac2f7" Type="Pathway" GroupRef="a3e09">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="AGT" GraphId="b6003" Type="GeneProduct" GroupRef="a3e09">
        </DataNode>
  <DataNode TextLabel="SARS-CoV-2 and&#10;COVID-19 pathway" GraphId="be0b0" Type="Pathway" GroupRef="a3e09">
    <Graphics ShapeType="RoundedRectangle" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="TMPRSS2" GraphId="eba5c" Type="GeneProduct" GroupRef="a3e09">
        </DataNode>
  <DataNode TextLabel="ACE2" GraphId="f33e8" Type="GeneProduct" GroupRef="a3e09">
        </DataNode>
  <Interaction GraphId="idf55cb6e4" GroupRef="c757c">
    <Comment>GeneMANIA predicted interaction</Comment>
    <Graphics ConnectorType="Elbow" LineStyle="Broken">
      <Point GraphRef="f425c"/>
      <Point/>
      <Point GraphRef="cf7c5"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id981d12bb" GroupRef="c757c">
    <Comment>GeneMANIA predicted interaction</Comment>
    <Graphics ConnectorType="Elbow" LineStyle="Broken">
      <Point GraphRef="f425c"/>
      <Point/>
      <Point GraphRef="ee6e7"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idfc67b63" GroupRef="c757c">
    <Comment>GeneMANIA predicted interaction</Comment>
    <Graphics ConnectorType="Elbow" LineStyle="Broken">
      <Point GraphRef="cf7c5"/>
      <Point/>
      <Point GraphRef="feac7"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id6de06d86" GroupRef="c757c">
    <Comment>GeneMANIA predicted interaction</Comment>
    <Graphics ConnectorType="Elbow" LineStyle="Broken">
      <Point GraphRef="cf7c5"/>
      <Point/>
      <Point GraphRef="eb71b"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idfe2de42e" GroupRef="c757c">
    <Comment>GeneMANIA identified physical interaction</Comment>
    <Graphics>
      <Point GraphRef="d380c"/>
      <Point GraphRef="f59b7"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idd81b881e" GroupRef="a3e09">
    <Comment>Proteolytic processing</Comment>
    <BiopaxRef>f09</BiopaxRef>
    <Graphics>
      <Point GraphRef="f33e8"/>
      <Point GraphRef="b6003" ArrowHead="mim-modification"/>
    </Graphics>
    </Interaction>
  <Label TextLabel="KE2" GraphId="bb627" GroupRef="c757c">
    <Comment/>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE1" GraphId="b61bc" GroupRef="c757c">
    <Comment/>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE3" GraphId="f446c" GroupRef="c757c">
    <Comment/>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="AO (KE:1751) - Increased mortality" GraphId="a32e5" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="MIE (KE:1739) - Binding of S protein to ACE receptor" GraphId="a5023" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Events related to the adverse outcome pathway for&#10;acute respiratory distress associated mortality (AOP:320)" GraphId="b40a2" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="15 genes included in the pathway:&#10;genes with direct evidence of association&#10;to COVID-19 in the Comparative Toxicogenomics Database&#10;(https://ctdbase.org)" GraphId="b8650">
    <Comment>As of 8th April, 2020</Comment>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE4 (KE:1748) -  &#9;Increase, the risk of acute respiratory failure" GraphId="bc4ba" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE1 (KE:1738) - Enhanced viral entry and gene expression" GraphId="be031" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE2 (KE:1496) - Increased, secretion of proinflammatory and profibrotic mediators" GraphId="d40df" GroupRef="c404e">
    <Comment>KE:1496 is also part of AOP:173 for lung fibrosis</Comment>
    <BiopaxRef>c88</BiopaxRef>
    <BiopaxRef>bab</BiopaxRef>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="MIE" GraphId="e8044" GroupRef="a3e09">
    <Comment>MIE in AOP:320 and AOP:319</Comment>
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Legend" GraphId="e98ed" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="KE3 (KE:1750) - Increase inflammatory immune responses" GraphId="f4516" GroupRef="c404e">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Shape GraphId="da506" GroupRef="c757c">
    <Comment>KE2 (KE:1496) is also part of the lung fibrosis pathway (WP3624) and AOP (AOP:173)</Comment>
    <BiopaxRef>bab</BiopaxRef>
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="abe7a" GroupRef="c757c">
    <Comment>Pathways and KEs associated with lung fibrosis (AOP:173)</Comment>
    <BiopaxRef>bab</BiopaxRef>
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="e69d3" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="e7d95" GroupRef="c757c">
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="d2977" GroupRef="c757c">
    <Comment>Associated with the MIE in Lung fibrosis AOP:173</Comment>
    <BiopaxRef>bab</BiopaxRef>
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="a11c4" GroupRef="a3e09">
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="de707" GroupRef="a3e09">
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Shape GraphId="c3cff" GroupRef="c404e">
    <Comment>Associated with the MIE in Lung fibrosis AOP:173</Comment>
    <Graphics ShapeType="RoundedRectangle"/>
  </Shape>
  <Group GroupId="c757c" Style="Group"/>
  <Group GroupId="c404e" Style="Group"/>
  <Group GroupId="a3e09" Style="Group"/>
  <InfoBox/>
  <Biopax>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >severe acute respiratory syndrome</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:2945</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >respiratory system disease pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0001308</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >pulmonary fibrosis</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:3770</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c88">
      <bp:ID >26979667</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes.</bp:TITLE>
      <bp:SOURCE >Part Fibre Toxicol</bp:SOURCE>
      <bp:YEAR >2016</bp:YEAR>
      <bp:AUTHORS >Labib S</bp:AUTHORS>
      <bp:AUTHORS >Williams A</bp:AUTHORS>
      <bp:AUTHORS >Yauk CL</bp:AUTHORS>
      <bp:AUTHORS >Nikota JK</bp:AUTHORS>
      <bp:AUTHORS >Wallin H</bp:AUTHORS>
      <bp:AUTHORS >Vogel U</bp:AUTHORS>
      <bp:AUTHORS >Halappanavar S</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bab">
      <bp:ID >29149350</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >A Data Fusion Pipeline for Generating and Enriching Adverse Outcome Pathway Descriptions.</bp:TITLE>
      <bp:SOURCE >Toxicol Sci</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Nymark P</bp:AUTHORS>
      <bp:AUTHORS >Rieswijk L</bp:AUTHORS>
      <bp:AUTHORS >Ehrhart F</bp:AUTHORS>
      <bp:AUTHORS >Jeliazkova N</bp:AUTHORS>
      <bp:AUTHORS >Tsiliki G</bp:AUTHORS>
      <bp:AUTHORS >Sarimveis H</bp:AUTHORS>
      <bp:AUTHORS >Evelo CT</bp:AUTHORS>
      <bp:AUTHORS >Hongisto V</bp:AUTHORS>
      <bp:AUTHORS >Kohonen P</bp:AUTHORS>
      <bp:AUTHORS >Willighagen E</bp:AUTHORS>
      <bp:AUTHORS >Grafstr&#246;m RC</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >viral infectious disease</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:934</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >COVID-19</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:0080600</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >signaling pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0000003</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f09">
      <bp:ID >10969042</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.</bp:TITLE>
      <bp:SOURCE >Circ Res</bp:SOURCE>
      <bp:YEAR >2000</bp:YEAR>
      <bp:AUTHORS >Donoghue M</bp:AUTHORS>
      <bp:AUTHORS >Hsieh F</bp:AUTHORS>
      <bp:AUTHORS >Baronas E</bp:AUTHORS>
      <bp:AUTHORS >Godbout K</bp:AUTHORS>
      <bp:AUTHORS >Gosselin M</bp:AUTHORS>
      <bp:AUTHORS >Stagliano N</bp:AUTHORS>
      <bp:AUTHORS >Donovan M</bp:AUTHORS>
      <bp:AUTHORS >Woolf B</bp:AUTHORS>
      <bp:AUTHORS >Robison K</bp:AUTHORS>
      <bp:AUTHORS >Jeyaseelan R</bp:AUTHORS>
      <bp:AUTHORS >Breitbart RE</bp:AUTHORS>
      <bp:AUTHORS >Acton S</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>